Business
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids
TiumBio (KRX: 321550.KQ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable disease, today announced that Merigolix (code name: TU2670, Daewon's code name: DW4902) has successfully met the primary endpoint of reducing heavy menstrual bleeding in a Phase 2 clinical trial for uterine fibroids. In this trial, Merigolix demonstrated statistically significant improvements across all dosage groups compared to p
About this update from Tiumbio Co., Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"Broader Therapeutic Potential: Positive Phase 2 results in both uterine fibroids and endometriosis could place Merigolix as a strong best-in-class candidate for novel drug approval and global licensing opportunities","length":220,"tagName":"p"}]},{"val":[{"type":"text","content":"Multi-Indication Development: Clinical trials are underway for three indications enhancing the asset value-uterine fibroids, endometriosis, and assisted reproductive technology (ART), the latter in collaboration with Hansoh Pharma in China","length":244,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":617,"olType":false},{"type":"text","content":"SEONGNAM, South Korea, May 7, 2025 /PRNewswire/ -- TiumBio (KRX: 321550.KQ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable disease, today announced that Merigolix (code name: TU2670, Daewon's code name: DW4902) has successfully met the primary endpoint of reducing heavy menstrual bleeding in a Phase 2 clinical trial for uterine fibroids. In this trial, Merigolix demonstrated statistically significant improvements across all dosage groups compared to placebo in patients with uterine fibroids.","length":596,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/TiumBio)","displaySize":"","headline":null,"caption":"(PRNewsfoto/TiumBio)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":167,"url":"https://media.zenfs.com/en/prnewswire.com/d564600e3d5ca4d6c2b423c122fd83f4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mv87UWHE0qRH4lOXLDmDzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI5NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d564600e3d5ca4d6c2b423c122fd83f4","width":400,"height":167}},"href":"https://mma.prnewswire.com/media/2308813/tiumbio_logo_horizontal_c__7_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Merigolix is an investigational, once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike traditional GnRH agonists, which require injection and ofte...